Cargando…
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer
INTRODUCTION: Adjuvant endocrine therapy induces bone loss and increases fracture risk in women with hormone-receptor positive, early-stage breast cancer (EBC). We aimed to update a previous position statement on the management of aromatase inhibitors (AIs) induced bone loss and now included premeno...
Autores principales: | Waqas, Komal, Lima Ferreira, Joana, Tsourdi, Elena, Body, Jean-Jacques, Hadji, Peyman, Zillikens, M.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080519/ https://www.ncbi.nlm.nih.gov/pubmed/33948427 http://dx.doi.org/10.1016/j.jbo.2021.100355 |
Ejemplares similares
-
Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy
por: Diana, Anna, et al.
Publicado: (2021) -
MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series
por: Mauceri, Rodolfo, et al.
Publicado: (2023) -
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
por: Hadji, Peyman, et al.
Publicado: (2017) -
Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study
por: Bryce, Jane, et al.
Publicado: (2012) -
Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer – a retrospective cohort study
por: Stumpf, Ulla, et al.
Publicado: (2020)